Announcement • 4h
Aristo Bio-Tech and Lifescience Limited to Report Second Half, 2026 Results on May 29, 2026 Aristo Bio-Tech and Lifescience Limited announced that they will report second half, 2026 results on May 29, 2026 Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹99.00, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 76% over the past three years. New Risk • Nov 24
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.0% Last year net profit margin: 1.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹834.0m market cap, or US$9.31m). Minor Risks High level of debt (79% net debt to equity). Share price has been volatile over the past 3 months (7.9% average weekly change). Profit margins are more than 30% lower than last year (1.0% net profit margin). Announcement • Nov 13
Aristo Bio-Tech and Lifescience Limited to Report First Half, 2026 Results on Nov 14, 2025 Aristo Bio-Tech and Lifescience Limited announced that they will report first half, 2026 results on Nov 14, 2025 Buy Or Sell Opportunity • Oct 15
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 8.0% to ₹135. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Buy Or Sell Opportunity • Sep 30
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 1.9% to ₹133. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Buy Or Sell Opportunity • Sep 12
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 20% to ₹136. The fair value is estimated to be ₹111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Board Change • Sep 08
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Aug 18
Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025 Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025, at 15:00 Indian Standard Time. Buy Or Sell Opportunity • Jun 02
Now 18% undervalued Over the last 90 days, the stock has risen 61% to ₹142. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%. New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks High level of debt (51% net debt to equity). Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹963.3m market cap, or US$11.3m). New Risk • May 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹844.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₹844.2m market cap, or US$9.86m). Minor Risk High level of debt (51% net debt to equity). Buy Or Sell Opportunity • May 16
Now 24% undervalued Over the last 90 days, the stock has risen 11% to ₹130. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%. Buy Or Sell Opportunity • Apr 25
Now 21% undervalued Over the last 90 days, the stock has risen 1.1% to ₹137. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%. Buy Or Sell Opportunity • Apr 07
Now 24% undervalued Over the last 90 days, the stock has risen 1.7% to ₹131. The fair value is estimated to be ₹174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹110, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 69% over the past year. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹105, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 18% over the past year. New Risk • Jan 14
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹837.4m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (₹837.4m market cap, or US$9.67m). Minor Risk High level of debt (51% net debt to equity). Board Change • Dec 18
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Dec 03
Now 22% undervalued Over the last 90 days, the stock has risen 44% to ₹143. The fair value is estimated to be ₹182, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%. Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹131, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 76% over the past year. Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹125, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 59% over the past year. Announcement • Sep 24
Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024 Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (₹722.6m market cap, or US$8.62m). Minor Risk Short dividend paying track record (1 year of continuous dividend payments). Announcement • Aug 30
Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024 Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024, at 15:00 Indian Standard Time. Declared Dividend • Aug 30
Dividend increased to ₹0.40 Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Valuation Update With 7 Day Price Move • Jun 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹90.35, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 54% over the past year. New Risk • May 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹539.5m market cap, or US$6.49m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹73.70, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year. Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹68.50, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year. New Risk • Mar 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹372.0m market cap, or US$4.49m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.9% average weekly change). Valuation Update With 7 Day Price Move • Mar 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹71.80, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 1.8% over the past year. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹80.05, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 11% over the past year. Valuation Update With 7 Day Price Move • Jan 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹85.00, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 6.3% over the past year. New Risk • Oct 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Share price has been highly volatile over the past 3 months (9.0% average weekly change). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹564.0m market cap, or US$6.77m). Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹69.55, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 22x in the Chemicals industry in India. New Risk • Jun 13
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹382.3m market cap, or US$4.64m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change). Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹64.00, the stock trades at a trailing P/E ratio of 30.1x. Average trailing P/E is 20x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹70.75, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 19x in the Chemicals industry in India. Reported Earnings • Jan 30
Full year 2022 earnings released: EPS: ₹2.90 (vs ₹2.15 in FY 2021) Full year 2022 results: EPS: ₹2.90 (up from ₹2.15 in FY 2021). Revenue: ₹1.66b (flat on FY 2021). Net income: ₹14.5m (up 35% from FY 2021). Profit margin: 0.9% (up from 0.6% in FY 2021). Board Change • Jan 30
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Surendra Lakhawat was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Jan 30
Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million. Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 860,800
Price\Range: INR 72
Discount Per Security: INR 5.1336
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 860,800
Price\Range: INR 72
Discount Per Security: INR 5.1336
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 91,200
Price\Range: INR 72
Discount Per Security: INR 5.1336
Transaction Features: Regulation S